Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
The New England Journal of Medicine
|
December 22, 2018
Parvovirus B19 Infection
Marika Mende, Katja Sockel
BMC Cancer
|
February 9, 2013
Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population
Marika Mende, Karolin Trautmann, Anke Rentsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2015
Siltuximab for Multicentric Castleman Disease-Letter
Raphael Teipel, Rainer Ordemann, Ulrike Proske, et al.
Frontiers in Genetics
|
January 24, 2022
Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer
Sebastian Stasik, Marika Mende, Caroline Schuster, et al.
The Lancet. Oncology
|
November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
The New England Journal of Medicine
|
December 22, 2018
Parvovirus B19 Infection
Marika Mende, Katja Sockel
BMC Cancer
|
February 9, 2013
Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population
Marika Mende, Karolin Trautmann, Anke Rentsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2015
Siltuximab for Multicentric Castleman Disease-Letter
Raphael Teipel, Rainer Ordemann, Ulrike Proske, et al.
Frontiers in Genetics
|
January 24, 2022
Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer
Sebastian Stasik, Marika Mende, Caroline Schuster, et al.
The Lancet. Oncology
|
November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Page
of 1